The literature review revealed only 2 other documented cases of NSCLC with concurrent SMARCA4 deficiency and EGFR or ALK mutations, complicating the ability to draw definitive conclusions regarding optimal treatment strategies for this specific subgroup. The gene discussed is ALK; the disease is non-small cell lung carcinoma.